Prostamax vs Triptorelin
Prostate-specific tetrapeptide bioregulator (Lys-Glu-Asp-Pro) that normalizes prostatic epithelial differentiation through chromatin remodeling at prostate gene promoters, restores the proliferation-apoptosis balance disrupted in benign prostatic hyperplasia, and reduces inflammatory cytokine signaling in aging prostate tissue
GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Prostamax
0.01–100 mcg/kg
Triptorelin
11.25–11.25 mg
Frequency
Prostamax
Once daily
Triptorelin
Once daily
Administration
Prostamax
Sublingual (enteric-coated capsules)
Triptorelin
Intramuscular injection
Cycle length
Prostamax
12+ weeks
Triptorelin
Ongoing/indefinite
Onset speed
Prostamax
Gradual (3-4 weeks)
Triptorelin
Moderate (1-2 weeks)
Evidence level
Prostamax
Limited human trials
Triptorelin
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Prostate Health
Urinary Function
Tissue Inflammation
Hormone Regulation
Cancer Management
Endometriosis Relief
Compound specifications
Prostamax
Molecular formula
C20H33N5O9
Molecular weight
487.5 g/mol
Half-life
Short plasma half-life typical of tetrapeptides (minutes to hours); biological effects persist for weeks to months through chromatin remodeling at prostate gene promoters; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) in oral formulation; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to short tetrapeptide structure with proline conferring conformational stability
CAS number
Not publicly registered
Triptorelin
Molecular formula
C64H82N18O13
Molecular weight
1311.4 g/mol
Half-life
2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)
Bioavailability
~100% (intramuscular/subcutaneous injection)
CAS number
57773-63-4
Dosing compared
Prostamax
Intramuscular
0.01-100 mcg/kg
Once daily · 10-40 days
Dose from a single-institute patent report in 35 chronic-prostatitis patients [6]. The wide range reflects dose-finding within that single report.
Oral
~10 mg
Once daily · 10-30 day course
Capsule form reflecting bioregulator product labeling and practice [1].
Triptorelin
Intramuscular injection
3.75 mg
Once every 4 weeks · Ongoing while indicated
FDA-labeled 1-month depot (Trelstar) for advanced prostate cancer; single IM injection into either buttock [5].
11.25 mg
Once every 12 weeks · Ongoing while indicated
FDA-labeled 3-month depot (Trelstar). Strengths are not additive; chosen by desired interval [5].
22.5 mg
Once every 24 weeks · Ongoing while indicated
FDA-labeled 6-month depot (Trelstar for prostate cancer; Triptodur 22.5 mg for central precocious puberty, ages 2+) [5][6].
Best suited for
Prostamax
Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization
Prostamax is particularly well-suited for individuals focused on age-related benign prostatic hyperplasia (bph) requiring tissue-level normalization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Prostate geroprotection — preserving prostatic epithelial function during aging
Prostamax is particularly well-suited for individuals focused on prostate geroprotection — preserving prostatic epithelial function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic prostatitis support through anti-inflammatory tissue-level mechanisms
Prostamax is particularly well-suited for individuals focused on chronic prostatitis support through anti-inflammatory tissue-level mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting male genitourinary health
Prostamax is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting male genitourinary health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Triptorelin
Managing advanced prostate cancer when combined with other treatments
Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving severe endometriosis pain and symptoms
Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Delaying puberty development in children with early sexual maturation
Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Prostamax
Common
- Injection site reaction
- Mild fatigue
- Urinary frequency changes
- Mild headache
Uncommon
- Mild pelvic discomfort
Serious
- No documented serious adverse effects
Triptorelin
Safety & evidence
Prostamax
Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Prostamax (proprietary peptide blend) demonstrates limited published safety data; primarily used in clinical practice based on observational evidence. No serious adverse events reported in clinical use; mild gastrointestinal tolerance issues occasionally reported. Derived from bovine prostatic tissue; potential allergenicity in beef-sensitive individuals requires screening. Quality control and standardization vary across manufacturers.
Contraindications
- Known or suspected prostate cancer — potential modulation of prostatic gene expression requires oncological clearance
- Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, proline)
- Severe urinary retention requiring surgical intervention — epigenetic therapy cannot address acute obstruction
- Concurrent anti-androgen therapy without medical supervision — potential interaction with hormonal mechanisms
Triptorelin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.
Contraindications
- Pregnancy (can affect fetal development)
- Undiagnosed vaginal bleeding
- Known hypersensitivity to GnRH agonists
- Severe untreated depression
- Active spinal cord compression in prostate cancer (requires urgent decompression)
Which is right for you?
Choose Prostamax if...
- Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization
- Prostate geroprotection — preserving prostatic epithelial function during aging
- Chronic prostatitis support through anti-inflammatory tissue-level mechanisms
- Comprehensive Khavinson bioregulator protocols targeting male genitourinary health
Choose Triptorelin if...
- Managing advanced prostate cancer when combined with other treatments
- Relieving severe endometriosis pain and symptoms
- Delaying puberty development in children with early sexual maturation